Электронный архив

Просмотр Публикации сотрудников КФУ Scopus по автору "Yakovlev I."

Просмотр Публикации сотрудников КФУ Scopus по автору "Yakovlev I."

Отсортировать по:Сортировать:Результаты поиска на странице:

  • Corrigendum: Twenty-year clinical progression of dysferlinopathy in patients from Dagestan [Front Neurol, 8, (2017) (77)] doi: 10.3389/fneur.2017.00077 
    Umakhanova Z.; Bardakov S.; Mavlikeev M.; Chernova O.; Magomedova R.; Akhmedova P.; Yakovlev I.; Dalgatov G.; Fedotov V.; Isaev A.; Deev R. (2017)
    The "Funding" section should be: This work was funded by Human Stem Cells Institute PJSC and Roman V. Deev. Theoretical part of this work was supported by Russian Scientific Foundation grant (14-15-00916). Ivan A. Yakovlev ...
  • Organic chemistry. History and mutual relations of universities of Russia 
    Antipin I.; Kazymova M.; Kuznetsov M.; Vasilyev A.; Ishchenko M.; Kiryushkin A.; Kuznetsova L.; Makarenko S.; Ostrovskii V.; Petrov M.; Solod O.; Trishin Y.; Yakovlev I.; Nenaidenko V.; Beloglazkina E.; Beletskaya I.; Ustynyuk Y.; Solov’ev P.; Ivanov I.; Malina E.; Sivova N.; Negrebetskii V.; Baukov Y.; Pozharskaya N.; Traven’ V.; Shchekotikhin A.; Varlamov A.; Borisova T.; Lesina Y.; Krasnokutskaya E.; Rogozhnikov S.; Shurov S.; Kustova T.; Klyuev M.; Khelevina O.; Stuzhin P.; Fedorov A.; Gushchin A.; Dodonov V.; Kolobov A.; Plakhtinskii V.; Orlov V.; Kriven’ko A.; Fedotova O.; Pchelintseva N.; Charushin V.; Chupakhin O.; Klimochkin Y.; Klimochkina A.; Kuryatnikov V.; Malinovskaya Y.; Levina A.; Zhuravlev O.; Voronchikhina L.; Fisyuk A.; Aksenov A.; Aksenov N.; Aksenova I. (2017)
    © 2017, Pleiades Publishing, Ltd. The review describes the history of development of organic chemistry in higher schools of Russia over a period of 170 years, since the emergence of organic chemistry in our country till now.
  • Pre- and posttranscriptional genetic information modification in muscular dystrophy treatment 
    Yakovlev I.; Deev R.; Solovyeva V.; Rizvanov A.; Isaev A. (2016)
    Nowadays, a whole range of genetherapeutic methods is being used to restore a lost protein function due to mutation, a big number of preclinical and clinical studies of potential drugs that may allow to implement an ...
  • RNA Editing for Muscular Dystrophy Therapy 
    Yakovlev I.; Deev R.; Rizvanov A.; Isaev A. (2017)
    © 2016, Springer Science+Business Media New York.Due to lack of effective therapies, muscular dystrophies became a focus for gene therapy. Multiple pre-clinical studies have shown successful restoration of dystrofin and ...
  • Serum Cytokine Profile in a Patient Diagnosed with Dysferlinopathy 
    Khaiboullina S.; Martynova E.; Bardakov S.; Mavlikeev M.; Yakovlev I.; Isaev A.; Deev R.; Rizvanov A. (2017)
    © 2017 Svetlana F. Khaiboullina et al. Limb-girdle muscular dystrophy type 2 (LGMD2B) is a mild form of dysferlinopathy, characterized by limb weakness and wasting. It is an autosomal recessive disease, with currently 140 ...
  • Twenty-year clinical progression of dysferlinopathy in patients from Dagestan 
    Umakhanova Z.; Bardakov S.; Mavlikeev M.; Chernova O.; Magomedova R.; Akhmedova P.; Yakovlev I.; Dalgatov G.; Fedotov V.; Isaev A.; Deev R. (2017)
    © 2017 Umakhanova, Bardakov, Mavlikeev, Chernova, Magomedova, Akhmedova, Yakovlev, Dalgatov, Fedotov, Isaev and Deev.To date, over 30 genes with mutations causing limb-girdle muscle dystrophy have been described. ...

Поиск в электронном архиве


Расширенный поиск

Просмотр

Моя учетная запись